Trial Profile
An exploratory placebo controlled, dose ranging study of the effects of TRx0014 [methylthioninium chloride] 30mg tid, 60mg tid and 100mg tid in patients with mild to moderate dementia of the Alzheimer type
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Methylthioninium chloride-TauRx (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors TauRx Therapeutics
- 31 Jul 2008 SPECT imaging results were published in the proceedings of the 12th International Conference on Alzheimer's Disease and Related Disorders.
- 31 Jul 2008 Positron emission tomography results were published in the proceedings of the 12th International Conference on Alzheimer's Disease and Related Disorders.
- 31 Jul 2008 Results were presented at the 12th International Conference on Alzheimer's Disease and Related Disorders.